glp 1 type 2 diabetes New GLP-1 Guidelines for in 2025 GLP-1 Receptor Agonists as Treatments

The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese adults

As the popularity of GLP-1 drugs continues to skyrocket, there has also been a huge rise in overdoses

In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy), a long-acting analog of the satiety hormone amylin, currently in phase I development.

Individual results may vary

Discover the evidence on GLP-1 receptor agonists in older adults, including safety considerations, side effects, dosing guidance, and monitoring requirements for elderly patients with diabetes.